The eosinophilic variant of chronic myeloid leukemia

The eosinophilic variant of chronic myeloid leukemia

Bibliographic Details
Main Author:	Stephen E. Langabeer
Format:	Article
Language:	English
Published:	IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund 2021-11-01
Series:	EXCLI Journal : Experimental and Clinical Sciences
Subjects:	chronic myeloid leukemia eosinophilic variant tyrosine kinase inhibitor
Online Access:	https://www.excli.de/index.php/excli/article/view/4462

Similar Items

The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia
by: Damla Eyüpoğlu, et al.
Published: (2016-02-01)

Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report
by: Michelle Hyunju Lee, et al.
Published: (2024-01-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

Second-Line Therapy Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib
by: Chici Pratiwi, et al.
Published: (2022-12-01)

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
by: Rinaldi I, et al.
Published: (2023-04-01)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Zhenshu Xu, et al.
Published: (2009-03-01)

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia
by: S. I. Kutsev, et al.
Published: (2010-06-01)

Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia
by: Mariarita Spampinato, et al.
Published: (2024-07-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Avital F. Barak, et al.
Published: (2011-12-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
by: Matteo Molica, et al.
Published: (2020-09-01)

Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
by: Irena Ćojbašić, et al.
Published: (2023-08-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
by: Franceli Carvalho, et al.
Published: (2016-12-01)

Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib
by: David Sanford, et al.
Published: (2014-06-01)

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report
by: T. Yu. Pavlova, et al.
Published: (2022-11-01)

Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia
by: Yingling Zu, et al.
Published: (2024-09-01)

Serum Calcium And Phosphateleveelsin Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors
by: Bassam Francis Matti, et al.
Published: (2018-03-01)

A review on characterization of BCR – ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
by: Benyam Zenebe, et al.
Published: (2023-12-01)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022-01-01)

COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
by: G. B. Kuchma, et al.
Published: (2022-07-01)

Autophagy and Cancer: Insights into Molecular Mechanisms and Therapeutic Approaches for Chronic Myeloid Leukemia
by: Mohd Adnan Kausar, et al.
Published: (2025-02-01)

Spontaneous Remission in a Patient with Chronic Myeloid Leukemia: A Case Report
by: Awni Alshurafa, et al.
Published: (2023-10-01)

Features of the etythropoesis upon treatment of chronic myeloid leukemia with tyrosine kinase inhibitor
by: I. Sviezhentseva, et al.
Published: (2016-07-01)

Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis
by: Zhenxiang Zheng, et al.
Published: (2024-10-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
by: Li Liu, et al.
Published: (2023-12-01)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu
Published: (2013-09-01)

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
by: Hijiya N, et al.
Published: (2023-08-01)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023-12-01)

Comparative evaluation of bone marrow cells morpho-functional activity in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors of the first and second generation
by: I. O. Zhaleyko, et al.
Published: (2014-07-01)

Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of <i>BCR::ABL1/A337V</i> Can Be Effectively Overcome with Dasatinib Treatment
by: Peter Batar, et al.
Published: (2025-02-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study
by: Mehmet Özen, et al.
Published: (2017-02-01)

The importance of personalized medicine in chronic myeloid leukemia management: a narrative review
by: Erfan Zaker, et al.
Published: (2023-04-01)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
by: Alejandro Zulbaran‐Rojas, et al.
Published: (2018-11-01)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021-11-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Chromosomal Aberrations in Chronic Myeloid Leukemia: Response to Conventional TKIs and Risk of Blastic Transformation
by: Shafaq Maqsood, et al.
Published: (2021-03-01)